Beating Leukemia with Groundbreaking CAR-T Cell Therapy

Beating Leukemia with Groundbreaking CAR-T Cell Therapy

Dr. Stephan A. Grupp made history when he treated the first child with CAR T cell therapy, Emily Whitehead, who is now more than five years cancer-free. In CAR-T cell therapy, a patient's own genetically altered immune cells fight cancer. We learnt about the CAR-T cell research journey and FDA approval in our discussion with Dr. Carl June of University of Pennsylvania in the first episode of our CAR-T talk series. In this episode, we are talking to Dr. Stephan A. Grupp who carried out the early pediatric trials and the global Novartis trial at CHOP leading to the FDA approval. The discussion would focus on required preparations, recovery phase and where this treatment can be availed. We will also be joined by Tom Whitehead, father of Emily Whitehead who will share his experience with the trial and progress of Emily post CAR-T cell therapy.

Panelists

Live Talk on April 25, 2018, 3 p.m. EST
</> Embed

CureTalks is an online Talk featuring a leading expert in conversation with a panel and the audience. The audience can ask questions from the panelists LIVE on the talk by dial-ing in. To hear the talk via phone or on-line, please add your email on the left; we will send you Live Talk access details. You can also write your questions in the Comments/Questions section below and your question maybe selected to be featured on the talk.

  25-04-2018 15:00 25-04-2018 23:59 Beating Leukemia with Groundbreaking CAR-T Cell Therapy <p>Dr. Stephan A. Grupp made history when he treated the first child with CAR T cell therapy, Emily Whitehead, who is now more than five years cancer-free. In CAR-T cell therapy, a patient's own genetically altered immune cells fight cancer. We learnt about the CAR-T cell research journey and FDA approval in our discussion with Dr. Carl June of University of Pennsylvania in the first episode of our CAR-T talk series. In this episode, we are talking to Dr. Stephan A. Grupp who carried out the early pediatric trials and the global Novartis trial at CHOP leading to the FDA approval. The discussion would focus on required preparations, recovery phase and where this treatment can be availed. We will also be joined by Tom Whitehead, father of Emily Whitehead who will share his experience with the trial and progress of Emily post CAR-T cell therapy.</p> USA Curetalks priya@trialx.com false DD/MM/YYYY



  • April 19, 2018, 3:35 p.m.  US/Eastern

    Any recent advances in the use of CAR-T for t-cell lymphomas..????

  • April 19, 2018, 2:47 p.m.  US/Eastern

    Can you share your perspective please on the Car T program at Novartis, versus the program at Glaxo and Legend Pharmaceuticals? Any other players in this space that you could highlight for us? Especially with differentiating points on one versus the other that are worth noting please. Owe you for all you do! Sincerely, Neal

  • Mike Palumbo April 19, 2018, 10:45 a.m.  US/Eastern

    How is this therapy being conducted to address multiple myeloma? Are they targeting BCMA, CD38, or CD19, a combination of these targets, or all of them?

  • kenny April 19, 2018, 5:50 a.m.  US/Eastern

    Is there an advisory board of researchers which will help guide a patient cancer support group to which immunotherapy platform is best matched with their particular tumor etiology? For example, CAR-T therapy vs ACT vs Crispr.

  • phil April 19, 2018, 5:48 a.m.  US/Eastern

    Will CAR-T cell therapy be considered for frontline treatment?

  • Amy April 16, 2018, 3:38 a.m.  US/Eastern

    What happens if the cancer cells mutate to not express the antigen anymore that the T-cells are targeted towards, would the therapy then lose its function ?

  • Nick April 16, 2018, 3:37 a.m.  US/Eastern

    What about children who have not relapsed...would they need to take a booster dose sometime in future to maintain their cancer free state.

  • susan April 16, 2018, 3:37 a.m.  US/Eastern

    Would a booster dose be given to patients who relapse?